Aviragen Therapeutics, Inc. |
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-35285
|
59-1212264
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
2500 Northwinds Parkway, Suite 100, Alpharetta, GA 30009 |
(Address of principal executive offices and zip code)
|
(678) 221-3350 |
Registrant’s telephone number, including area code:
|
Not Applicable |
(Former name or former address, if changed since last report)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under The Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under The Exchange Act (17 CFR 240.13e-4(c)) |
Aviragen Therapeutics, Inc. | |||
Date: July 15, 2016
|
/s/ Joseph M. Patti
|
||
Name: | Joseph M. Patti | ||
Title:
|
Chief Executive Officer and President
(Duly Authorized Officer)
|